Reprogrammed metabolism is a hallmark of cancer. However, the metabolic dependency of
cancer, from tumour initiation through disease progression and therapy resistance, requires …

Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …

Summary The KRAS G12D mutation is present in nearly half of pancreatic adenocarcinomas
(PDAC). We investigated the effects of inhibiting the KRAS G12D mutant protein with …

TH 2 cells and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-
tumorigenic cytokines such as interleukin-4 (IL-4), IL-5, and IL-13. However, the …

Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This
reprogramming is driven by the combined actions of oncogenic alterations in cancer cells …

Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Cancer stem cells (CSCs) are self-renewing cells that facilitate tumor initiation, promote
metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many …

Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …